WHAT IS CLAIMED IS:

1. A crystalline salt form of Compound (1)



,

wherein the crystalline salt form is a hydrochloride salt having an X-ray powder diffraction pattern comprising peaks at approximately 9.7, 10.1, 14.3, 15.0, 17.5, 18.9, 21.9, and 23.7 degrees 2θ.

2. The crystalline salt according to claim 1, wherein the crystalline salt form is a hydrochloride salt having a differential scanning calorimetry thermogram endotherm T_{onset} at approximately 252 °C and an X-ray powder diffraction pattern comprising peaks at approximately 9.7, 10.1, 14.3, 15.0, 17.5, 18.9, 21.9, and 23.7 degrees 2θ.

3. A crystalline salt form of Compound (1)



,

wherein the crystalline salt form is a sulfate salt having an X-ray powder diffraction pattern comprising peaks at approximately 8.4, 12.6, 13.7, 16.7, 21.0, 21.8, 22.2, and 23.4 degrees 2θ.

4. The crystalline salt form according to claim 3, wherein the crystalline salt form is a sulfate salt having a differential scanning calorimetry thermogram endotherm T_{onset} at approximately 229 °C and an X-ray powder diffraction pattern comprising peaks at approximately 8.4, 12.6, 13.7, 16.7, 21.0, 21.8, 22.2, and 23.4 degrees 2θ.

5. A pharmaceutical composition comprising the crystalline salt form of any one of claims 1 to 4, and a pharmaceutically acceptable carrier.

6. The pharmaceutical composition of claim 5, which is a single unit dosage form.

7. The pharmaceutical composition according to claim 5, wherein the crystalline salt form is in substantially pure form.

8. Use of the pharmaceutical composition according to any one of claims 5 to 7 in the manufacture of a medicament for treating chronic pain, anxiety, insomnia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome in a mammal.

9. Use of a therapeutically-effective amount of the crystalline salt form according to any one of claims 1 to 4 in the manufacture of a medicament for treating chronic pain, anxiety, insomnia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome in a mammal comprising administering to the mammal.

10. The use according to claim 9, wherein the therapeutically-effective amount of the crystalline salt form is 5 mg to 500 mg.